home / stock / sgen / sgen articles

SGEN Articles, Seagen Inc. - From 11/03/23

Stock Information
Company Name: Seagen Inc.
Stock Symbol: SGEN
Market: NASDAQ
Website: seagen.com
Menu
SGEN SGEN Quote SGEN Short SGEN News SGEN Articles SGEN Message Board
Get SGEN Alerts

News, Short Squeeze, Breakout and More Instantly...
Here's How Much You Would Have Made Owning Seagen Stock In The Last 15 Years | Benzinga

Seagen (NASDAQ:SGEN) has outperformed the market over the past 15 years by 11.59% on an annualized basis producing an average annual return of 22.4...
Here's How Much $1000 Invested In Seagen 5 Years Ago Would Be Worth Today | Benzinga

Seagen (NASDAQ:SGEN) has outperformed the market over the past 5 years by 15.19% on an annualized basis producing an average annual return of 24.8%...

Merck's Best Selling Cancer Drug Meets One Goal In Late-Stage Bladder Cancer Study | Benzinga

Merck & Co Inc (NYSE: MRK) announced that the Phase 3 AMBASSADOR (A031501) trial (KEYNOTE-123) evaluating Keytruda met one of its dual pri...

If You Invested $100 In This Stock 20 Years Ago, You Would Have $3,400 Today | Benzinga

Seagen (NASDAQ:SGEN) has outperformed the market over the past 20 years by 12.02% on an annualized basis producing an average annual return of 19.3...
Why Is Seagen Stock Trading Higher Today? | Benzinga

Seagen Inc (NASDAQ: SGEN) and Astellas Pharma Inc (OTC: ALPMF) (OTC: ALPMY) released topline results from the KEYNOTE-A39 Phase...

$1000 Invested In This Stock 15 Years Ago Would Be Worth $16,000 Today | Benzinga

Seagen (NASDAQ:SGEN) has outperformed the market over the past 15 years by 11.54% on an annualized basis producing an average annual return of 20.9...

Why Is Cancer Focused Nurix Therapeutics Stock Trading Higher Today? | Benzinga

Nurix Therapeutics Inc (NASDAQ: NRIX) has entered into a multi-year, multi-target strategic collaboration agreement with Seagen Inc ...
Pyxis Oncology M&A Spotlight Signals Potential Growth Amidst Competitive ADC Landscape: Analyst | Benzinga

RBC Capital Markets has initiated coverage on Pyxis Oncology Inc (NASDAQ: PYXS) with an Outperform rating and a price target of...

Encouraging Data From Seagen/Genmab's Cervical Cancer Study - Tivdak Success Sets Stage For New Indications | Benzinga

Seagen Inc (NASDAQ: SGEN) and Genmab A/S (NASDAQ: GMAB) released topline data from the Phase 3 innovaTV 301 global trial in recurren...

Previous 10 Next 10